Methodologies for the isolation of alternative binders with improved clinical potentiality over conventional antibodies

References

• Abe Y, Yoshikawa T, Inoue M, Nomura T, Furuya T, Yamashita T, Nagano K, Nabeshi H, Yoshioka Y, Mukai Y, Nakagawa S, Kamada H, Tsutsumi Y, Tsunoda S. 2011. Fine tuning of receptor-selectivity for tumor necrosis factor-a using a phage display system with one-step competitive panning. Biomaterials 32: 5498–5504.
   Google Scholar
• Aliprandi M, Sparacio E, Pivetta F, Ossolengo G, Maestro R, de Marco A. 2010. The availability of a recombinant anti-SNAP antibody in VHH format amplifies the application flexibility of SNAP-tagged proteins. J Biomed Biotechnol 2010: 658954.
   Google Scholar
• An Z. 2010. Monoclonal antibodies - a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell 1: 319–330.
   PubMed Web of Science ®Google Scholar
• Baselga J, Gelmon KA, Verma S, Wardley A, Conte P, Miles D, Bianchi G, Cortes J, McNally VA, Ross GA, Fumoleau P, Gianni L. 2010. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28: 1138–1144.
   PubMed Web of Science ®Google Scholar
• Bédouet L, Arnold F, Robreau G, Batina P, Talbot F, Malcoste R. 1998. Partial analysis of the flagellar antigenic determinant recognized by a monoclonal antibody to Clostridium tyrobutyricum. Microbiol Immunol 42: 87–95.
   Google Scholar
• Bélizaire AK, Tchistiakova L, St-Pierre Y, Alakhov V. 2003. Identification of a murine ICAM-1-specific peptide by subtractive phage library selection on cells. Biochem Biophys Res Commun 309: 625–630.
   PubMed Web of Science ®Google Scholar
• Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. 2009. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci USA 106: 3294–3299.
   PubMed Web of Science ®Google Scholar
• Binz HK, Amstutz P, Kohl A, Stumpp MT, Briand C, Forrer P, Grütter MG, Plückthun A. 2004. High-affinity binders selected from designed ankyrin repeat protein libraries. Nat Biotechnol 22: 575–582.
   PubMed Web of Science ®Google Scholar
• Boersma YL, Chao G, Steiner D, Wittrup KD, Plückthun A. 2011. Bispecific designed ankyrin repeat proteins (DARPins) targeting epidermal growth factor receptor inhibit A431 cell proliferation and receptor recycling. J Biol Chem 286: 41273–41285.
   PubMed Web of Science ®Google Scholar
• Boltz A, Piater B, Toleikis L, Guenther R, Kolmar H, Hock B. 2011. Bi-specific aptamers mediating tumor cell lysis. J Biol Chem 286: 21896–21905.
   PubMed Web of Science ®Google Scholar
• Brabec V, Vrana O, Kiseleva VI, Poverenny AM. 1991. Polyclonal antibodies elicited against trans-diamminedichloroplatinum(II)-modified DNA and their application in nonradioactive hybridization experiments. Eur J Biochem 201: 723–730.
   Google Scholar
• Bradbury AR, Sidhu S, Dübel S, McCafferty J. 2011. Beyond natural antibodies: the power ofin vitrodisplay technologies. Nat Biotechnol 29: 245–254.
   PubMed Web of Science ®Google Scholar
• Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW, Sawyer LS, Hendry RM, Dunlop N, Nara PL. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266: 1024–1027.
   PubMed Web of Science ®Google Scholar
• Chames P, Coulon S, Baty D. 1998. Improving the affinity and the fine specificity of an anti-cortisol antibody by parsimonious mutagenesis and phage display. J Immunol 161: 5421–5429.
   PubMed Web of Science ®Google Scholar
• Chao G, Lau WL, Hackel BJ, Sazinsky SL, Lippow SM, Wittrup KD. 2006. Isolating and engineering human antibodies using yeast surface display. Nat Protoc 1: 755–768.
   PubMed Web of Science ®Google Scholar
• Els Conrath K, Lauwereys M, Wyns L, Muyldermans S. 2001. Camel single-domain antibodies as modular building units in bispecific and bivalent antibody constructs. J Biol Chem 276: 7346–7350.
   PubMed Web of Science ®Google Scholar
• Dolk E, van der Vaart M, Lutje Hulsik D, Vriend G, de Haard H, Spinelli S, Cambillau C, Frenken L, Verrips T. 2005. Isolation of llama antibody fragments for prevention of dandruff by phage display in shampoo. Appl Environ Microbiol 71: 442–450.
   PubMed Web of Science ®Google Scholar
• Doña V, Urrutia M, Bayardo M, Alzogaray V, Goldbaum FA, Chirdo FG. 2010. Single domain antibodies are specially suited for quantitative determination of gliadins under denaturing conditions. J Agric Food Chem 58: 918–926.
   PubMedGoogle Scholar
• Eggel A, Baumann MJ, Amstutz P, Stadler BM, Vogel M. 2009. DARPins as bispecific receptor antagonists analyzed for immunoglobulin E receptor blockage. J Mol Biol 393: 598–607.
   Google Scholar
• Eggel A, Buschor P, Baumann MJ, Amstutz P, Stadler BM, Vogel M. 2011. Inhibition of ongoing allergic reactions using a novel anti-IgE DARPin-Fc fusion protein. Allergy 66: 961–968.
   PubMed Web of Science ®Google Scholar
• Forsman A, Beirnaert E, Aasa-Chapman MM, Hoorelbeke B, Hijazi K, Koh W, Tack V, Szynol A, Kelly C, McKnight A, Verrips T, de Haard H, Weiss RA. 2008. Llama antibody fragments with cross-subtype human immunodeficiency virus type 1 (HIV-1)-neutralizing properties and high affinity for HIV-1 gp120. J Virol 82: 12069–12081.
   PubMed Web of Science ®Google Scholar
• Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX. 2004. Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5: 317–328.
   PubMed Web of Science ®Google Scholar
• Friedman LM, Rinon A, Schechter B, Lyass L, Lavi S, Bacus SS, Sela M, Yarden Y. 2005. Synergistic down-regulation of receptor tyrosine kinases by combinations of mAbs: implications for cancer immunotherapy. Proc Natl Acad Sci USA 102: 1915–1920.
   PubMed Web of Science ®Google Scholar
• Gavrilyuk JI, Wuellner U, Salahuddin S, Goswami RK, Sinha SC, Barbas CF 3rd. 2009. An efficient chemical approach to bispecific antibodies and antibodies of high valency. Bioorg Med Chem Lett 19: 3716–3720.
   Google Scholar
• Gruszka AM, Martinelli C, Sparacio E, Pelicci PG, de Marco A. 2012. The concurrent use of N- and C-terminal antibodies anti-nucleophosmin 1 in immunofluorescence experiments allows for precise assessment of its subcellular localisation in acute myeloid leukaemia patients. Leukemia 26: 159–162.
   Google Scholar
• Hagay Y, Lahav J, Levanon A, Panet A. 2003. Function-modulating human monoclonal antibodies against platelet-membrane receptors isolated from a phage-display library. J Thromb Haemost 1: 1829–1836.
   Google Scholar
• Hmila I, Abdallah R BA, Saerens D, Benlasfar Z, Conrath K, Ayeb ME, Muyldermans S, Bouhaouala-Zahar B. 2008. VHH, bivalent domains and chimeric Heavy chain-only antibodies with high neutralizing efficacy for scorpion toxin AahI’. Mol Immunol 45: 3847–3856.
   PubMedGoogle Scholar
• Hmila I, Saerens D, Ben Abderrazek R, Vincke C, Abidi N, Benlasfar Z, Govaert J, El Ayeb M, Bouhaouala-Zahar B, Muyldermans S. 2010. A bispecific nanobody to provide full protection against lethal scorpion envenoming. FASEB J 24: 3479–3489.
   PubMed Web of Science ®Google Scholar
• Hynes NE, Lane HA. 2005. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5: 341–354.
   PubMed Web of Science ®Google Scholar
• Kamat V, Donaldson JM, Kari C, Quadros MR, Lelkes PI, Chaiken I, Cocklin S, Williams JC, Papazoglou E, Rodeck U. 2008. Enhanced EGFR inhibition and distinct epitope recognition by EGFR antagonistic mAbs C225 and 425. Cancer Biol Ther 7: 726–733.
   PubMed Web of Science ®Google Scholar
• Kim J, Smith T, Idamakanti N, Mulgrew K, Kaloss M, Kylefjord H, Ryan PC, Kaleko M, Stevenson SC. 2002. Targeting adenoviral vectors by using the extracellular domain of the coxsackie-adenovirus receptor: improved potency via trimerization. J Virol 76: 1892–1903.
   Google Scholar
• Kortt AA, Dolezal O, Power BE, Hudson PJ. 2001. Dimeric and trimeric antibodies: high avidity scFvs for cancer targeting. Biomol Eng 18: 95–108.
   PubMedGoogle Scholar
• Jackman J, Chen Y, Huang A, Moffat B, Scheer JM, Leong SR, Lee WP, Zhang J, Sharma N, Lu Y, Iyer S, Shields RL, Chiang N, Bauer MC, Wadley D, Roose-Girma M, Vandlen R, Yansura DG, Wu Y, Wu LC. 2010. Development of a two-part strategy to identify a therapeutic human bispecific antibody that inhibits IgE receptor signaling. J Biol Chem 285: 20850–20859.
   PubMed Web of Science ®Google Scholar
• Jähnichen S, Blanchetot C, Maussang D, Gonzalez-Pajuelo M, Chow KY, Bosch L, De Vrieze S, Serruys B, Ulrichts H, Vandevelde W, Saunders M, De Haard HJ, Schols D, Leurs R, Vanlandschoot P, Verrips T, Smit MJ. 2010. CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells. Proc Natl Acad Sci USA 107: 20565–20570.
   PubMed Web of Science ®Google Scholar
• Jeong KJ, Jang SH, Velmurugan N. 2011. Recombinant antibodies: engineering and production in yeast and bacterial hosts. Biotechnol J 6: 16–27.
   Google Scholar
• Jimenez X, Lu D, Brennan L, Persaud K, Liu M, Miao H, Witte L, Zhu Z. 2005. A recombinant, fully human, bispecific antibody neutralizes the biological activities mediated by both vascular endothelial growth factor receptors 2 and 3. Mol Cancer Ther 4: 427–434.
   PubMed Web of Science ®Google Scholar
• Larbouret C, Robert B, Navarro-Teulon I, Thèzenas S, Ladjemi MZ, Morisseau S, Campigna E, Bibeau F, Mach JP, Pèlegrin A, Azria D. 2007. In vivotherapeutic synergism of anti-epidermal growth factor receptor and anti-HER2 monoclonal antibodies against pancreatic carcinomas. Clin Cancer Res 13: 3356–3362.
   PubMed Web of Science ®Google Scholar
• Laventie BJ, Rademaker HJ, Saleh M, de Boer E, Janssens R, Bourcier T, Subilia A, Marcellin L, van Haperen R, Lebbink JH, Chen T, Prévost G, Grosveld F, Drabek D. 2011. Heavy chain-only antibodies and tetravalent bispecific antibody neutralizing Staphylococcus aureus leukotoxins. Proc Natl Acad Sci USA 108: 16404–16409.
   PubMed Web of Science ®Google Scholar
• Li S, Kussie P, Ferguson KM. 2008. Structural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8. Structure 16: 216–227.
   PubMed Web of Science ®Google Scholar
• Li J, Lundberg E, Vernet E, Larsson B, Höidén-Guthenberg I, Gräslund T. 2010. Selection of affibody molecules to the ligand-binding site of the insulin-like growth factor-1 receptor. Biotechnol Appl Biochem 55: 99–109.
   Google Scholar
• de Marco A. 2011. Biotechnological applications of recombinant single-domain antibody fragments. Microb Cell Fact 10: 44.
   Google Scholar
• Martin CD, Rojas G, Mitchell JN, Vincent KJ, Wu J, McCafferty J, Schofield DJ. 2006. A simple vector system to improve performance and utilisation of recombinant antibodies. BMC Biotechnol 6: 46.
   PubMedGoogle Scholar
• Meulemans EV, Slobbe R, Wasterval P, Ramaekers FC, van Eys GJ. 1994. Selection of phage-displayed antibodies specific for a cytoskeletal antigen by competitive elution with a monoclonal antibody. J Mol Biol 244: 353–360.
   PubMedGoogle Scholar
• Meulemans EV, Nieland LJ, Debie WH, Ramaekers FC, van Eys GJ. 1995. Phage displayed antibodies specific for a cytoskeletal antigen. Selection by competitive elution with a monoclonal antibody. Hum Antibodies Hybridomas 6: 113–118.
   Google Scholar
• Monegal A, Ami D, Martinelli C, Huang H, Aliprandi M, Capasso P, Francavilla C, Ossolengo G, de Marco A. 2009. Immunological applications of single-domain llama recombinant antibodies isolated from a naïve library. Protein Eng Des Sel 22: 273–280.
   PubMed Web of Science ®Google Scholar
• Mortensen HD, Dupont K, Jespersen L, Willats WG, Arneborg N. 2007. Identification of amino acids involved in the Flo11p-mediated adhesion of Saccharomyces cerevisiae to a polystyrene surface using phage display with competitive elution. J Appl Microbiol 103: 1041–1047.
   Google Scholar
• Moutel S, El Marjou A, Vielemeyer O, Nizak C, Benaroch P, Dübel S, Perez F. 2009. A multi-Fc-species system for recombinant antibody production. BMC Biotechnol 9: 14.
   Google Scholar
• Muda M, Gross AW, Dawson JP, He C, Kurosawa E, Schweickhardt R, Dugas M, Soloviev M, Bernhardt A, Fischer D, Wesolowski JS, Kelton C, Neuteboom B, Hock B. 2011. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies. Protein Eng Des Sel 24: 447–454.
   Google Scholar
• Nilsson I, Bahram F, Li X, Gualandi L, Koch S, Jarvius M, Söderberg O, Anisimov A, Kholová I, Pytowski B, Baldwin M, Ylä-Herttuala S, Alitalo K, Kreuger J, Claesson-Welsh L. 2010. VEGF receptor 2/-3 heterodimers detected in situ by proximity ligation on angiogenic sprouts. EMBO J 29: 1377–1388.
   PubMed Web of Science ®Google Scholar
• Olichon A, Schweizer D, Muyldermans S, de Marco A. 2007. Heating as a rapid purification method for recovering correctly-folded thermotolerant VH and VHH domains. BMC Biotechnol 7: 7.
   PubMed Web of Science ®Google Scholar
• Pedersen MW, Jacobsen HJ, Koefoed K, Hey A, Pyke C, Haurum JS, Kragh M. 2010. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy. Cancer Res 70: 588–597.
   PubMed Web of Science ®Google Scholar
• Persaud K, Tille JC, Liu M, Zhu Z, Jimenez X, Pereira DS, Miao HQ, Brennan LA, Witte L, Pepper MS, Pytowski B. 2004. Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C. J Cell Sci 117: 2745–2756.
   PubMed Web of Science ®Google Scholar
• Plagmann I, Chalaris A, Kruglov AA, Nedospasov S, Rosenstiel P, Rose-John S, Scheller J. 2009. Transglutaminase-catalyzed covalent multimerization of Camelidae anti-human TNF single domain antibodies improves neutralizing activity. J Biotechnol 142: 170–178.
   PubMed Web of Science ®Google Scholar
• Roovers RC, Laeremans T, Huang L, De Taeye S, Verkleij AJ, Revets H, de Haard HJ, van Bergen en Henegouwen PM. 2007. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol Immunother 56: 303–317.
   PubMed Web of Science ®Google Scholar
• Roovers RC, Vosjan MJ, Laeremans T, El Khoulati R, de Bruin RC, Ferguson KM, Verkleij AJ, van Dongen GA, van Bergen En Henegouwen PM. 2011. A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth. Int J Cancer. DOI: 10.1002/ljc.26145.
   Google Scholar
• Rossi EA, Goldenberg DM, Chang CH. 2012. The Dock-and-Lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures. Bioconjug Chem PMID 22168393.
   Google Scholar
• Scanlan CN, Pantophlet R, Wormald MR, Ollmann Saphire E, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR. 2002. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1–>2 mannose residues on the outer face of gp120. J Virol 76: 7306–7321.
   PubMed Web of Science ®Google Scholar
• Spangler JB, Neil JR, Abramovitch S, Yarden Y, White FM, Lauffenburger DA, Wittrup KD. 2010. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc Natl Acad Sci USA 107: 13252–13257.
   PubMed Web of Science ®Google Scholar
• Stefan N, Martin-Killias P, Wyss-Stoeckle S, Honegger A, Zangemeister-Wittke U, Plückthun A. 2011. DARPins recognizing the tumor-associated antigen EpCAM selected by phage and ribosome display and engineered for multivalency. J Mol Biol 413: 826–843.
   PubMed Web of Science ®Google Scholar
• Stewart CS, MacKenzie CR, Hall JC. 2007. Isolation, characterization and pentamerization of alpha-cobrotoxin specific single-domain antibodies from a naïve phage display library: preliminary findings for antivenom development. Toxicon 49: 699–709.
   PubMedGoogle Scholar
• Stone E, Hirama T, Tanha J, Tong-Sevinc H, Li S, MacKenzie CR, Zhang J. 2007a. The assembly of single domain antibodies into bispecific decavalent molecules. J Immunol Methods 318: 88–94.
   PubMed Web of Science ®Google Scholar
• Stone E, Hirama T, Chen W, Soltyk AL, Brunton J, MacKenzie CR, Zhang J. 2007b. A novel pentamer versus pentamer approach to generating neutralizers of verotoxin 1. Mol Immunol 44: 2487–2491.
   Google Scholar
• Tvorogov D, Anisimov A, Zheng W, Leppänen VM, Tammela T, Laurinavicius S, Holnthoner W, Heloterä H, Holopainen T, Jeltsch M, Kalkkinen N, Lankinen H, Ojala PM, Alitalo K. 2010. Effective suppression of vascular network formation by combination of antibodies blocking VEGFR ligand binding and receptor dimerization. Cancer Cell 18: 630–640.
   PubMed Web of Science ®Google Scholar
• Ulrichts H, Silence K, Schoolmeester A, de Jaegere P, Rossenu S, Roodt J, Priem S, Lauwereys M, Casteels P, Van Bockstaele F, Verschueren K, Stanssens P, Baumeister J, Holz JB. 2011. Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs. Blood 118: 757–765.
   PubMed Web of Science ®Google Scholar
• Valabrega G, Montemurro F, Aglietta M. 2007. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 18: 977–984.
   PubMed Web of Science ®Google Scholar
• Veggiani G, de Marco A. 2011. Improved quantitative and qualitative production of single-domain intrabodies mediated by the co-expression of Erv1p sulfhydryl oxidase. Protein Expr Purif 79: 111–114.
   PubMed Web of Science ®Google Scholar
• Veggiani G, Ossolengo G, Aliprandi M, Cavallaro U, de Marco A. 2011. Single-domain antibodies that compete with the natural ligand fibroblast growth factor block the internalization of the fibroblast growth factor receptor 1. Biochem Biophys Res Commun 408: 692–696.
   PubMed Web of Science ®Google Scholar
• Wölcke J, Weinhold E. 2001. A DNA-binding peptide from a phage display library. Nucleosides Nucleotides Nucleic Acids 20: 1239–1241.
   PubMed Web of Science ®Google Scholar
• Zhang J, Tanha J, Hirama T, Khieu NH, To R, Tong-Sevinc H, Stone E, Brisson JR, MacKenzie CR. 2004. Pentamerization of single-domain antibodies from phage libraries: a novel strategy for the rapid generation of high-avidity antibody reagents. J Mol Biol 335: 49–56.
   PubMed Web of Science ®Google Scholar
• Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, Zhang PF, Bouma P, Zwick M, Choudhary A, Montefiori DC, Broder CC, Burton DR, Quinnan GV Jr, Dimitrov DS. 2004. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol 78: 9233–9242.
   PubMed Web of Science ®Google Scholar
• Zhu X, Wang L, Liu R, Flutter B, Li S, Ding J, Tao H, Liu C, Sun M, Gao B. 2010. COMBODY: one-domain antibody multimer with improved avidity. Immunol Cell Biol 88: 667–675.
   PubMedGoogle Scholar